Drug Trial Radar · NCT07926048
A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
420
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Dec 2029
Study completion Jan 2030
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this interventional study is to compare the effectiveness and safety of QLS5132 monotherapy with investigator's choice of chemotherapy in participants with platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Conditions
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
Interventions
QLS5132Drug
Intravenous infusion, Q3W (Day 1 of each 21-day cycle)
Liposomal DoxorubicinDrug
Intravenous infusion, Q4W (Day 1 of each 28-day cycle)
PaclitaxelDrug
Intravenous infusion, Q4W (Days 1, 8, 15, and 22 of each 28-day cycle)
TopotecanDrug
Intravenous infusion, Q4W (Days 1, 8, and 15 of each 28-day cycle)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) Assessed by BICRTime frame: From randomization to the first documented disease progression as assessed by blinded independent central review (BICR) using RECIST v1.1, or death from any cause, whichever occurs first, assessed up to approximately 3 years.
- Overall Survival (OS)Time frame: From randomization until death from any cause, assessed up to approximately 3 years.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.